The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Oncolytic Viruses in Cancer Treatment: A Review
Open accessAbstract
IMPORTANCE: Oncolytic viruses (OVs) are emerging as important agents in cancer treatment. Oncolytic viruses offer the attractive therapeutic combination of tumor-specific cell lysis together with immune stimulation, therefore acting as potential in situ tumor vaccines. Moreover, OVs can be engineered for optimization of tumor selectivity and enhanced immune stimulation and can be readily combined with other agents. The effectiveness of OVs has been demonstrated in many preclinical studies and recently in humans, with US Food and Drug Administration approval of the oncolytic herpesvirus talimogene laherparepvec in advanced melanoma, a major breakthrough for the field. Thus, the OV approach to cancer therapy is becoming more interesting for scientists, clinicians, and the public. The main purpose of this review is to give a basic overview of OVs in clinical development and provide a description of the current status of clinical trials. OBSERVATIONS: In 2016 approximately 40 clinical trials are recruiting patients, using a range of OVs in multiple cancer types. There are also many more trials in the planning stages. Therefore, we are now in the most active period of clinical OV studies in the history of the field. There are several OVs currently being tested with many additional engineered derivatives. In OV clinical trials, there are a number of specific areas that should be considered, including viral pharmacokinetics and pharmacodynamics, potential toxic effects, and monitoring of the patients' immune status. Clinical development of OVs is increasingly focused on their immune stimulatory properties, which may work synergistically with immune checkpoint inhibitors and other strategies in the treatment of human cancer. CONCLUSIONS AND RELEVANCE: Oncolytic viruses are an active area of clinical research. The ability of these agents to harness antitumor immunity appears to be key for their success. Combinatorial studies with immune checkpoint blockade have started and the results are awaited with great interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
Reovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., & Kirn, D. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 583
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Self-citationREGRESSION OF BURKITT'S LYMPHOMA IN ASSOCIATION WITH MEASLES INFECTION
Bluming, A., & Ziegler, J. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92086-1 · Cited by 410
Oncolytic Viruses and Their Application to Cancer Immunotherapy
Chiocca, E. A., & Rabkin, S. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0015 · Cited by 408
Self-citationTargeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O’Neil, J. D., Groene, W. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.042 · Cited by 385
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S. S., Yu, J., Kaur, B., Louis, D. N., Weissleder, R., Caligiuri, M. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605496103 · Cited by 357
Self-citationPoliovirus Cell Entry: Common Structural Themes in Viral Cell Entry Pathways
Hogle, J. M. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160757 · Cited by 352
Harrow, S., Papanastassiou, V, Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. M., & Rampling, R. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302289 · Cited by 342
Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Tsang, K. Y., Poole, D. J., Parnes, H. L., Wright, J. J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70006-2 · Cited by 326
Markert, J. M., Razdan, S. N., Kuo, H.-C., Cantor, A., Knoll, A., Karrasch, M., Nabors, L. B., Markiewicz, M., Agee, B. S., Coleman, J. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.22 · Cited by 319
Vesicular stomatitis virus: re-inventing the bullet
Lichty, B. D., Power, A. T., Stojdl, D. F., & Bell, J. C. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.03.003 · Cited by 319
Rationale for anti-OX40 cancer immunotherapy
Aspeslagh, S., Postel-Vinay, S., Rusakiewicz, S., Soria, J.-C., Zitvogel, L., & Marabelle, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.021 · Cited by 318
Clinical Trials with Oncolytic Adenovirus in China
Yu, W., & Fang, H. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780058817 · Cited by 274
Kambara, H., Okano, H., Chiocca, E. A., & Saeki, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3227 · Cited by 263
Self-citationTrial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions
Zamarin, D., & Palese, P. (2012) · Future Microbiology · doi:10.2217/fmb.12.4 · Cited by 254
Herpes Simplex Viruses: Mechanisms of DNA Replication
Weller, S. K., & Coen, D. M. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a013011 · Cited by 238
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer
Hastie, E., & Grdzelishvili, V. Z. (2012) · Journal of General Virology · doi:10.1099/vir.0.046672-0 · Cited by 226
Goldsmith, K., Chen, W., Johnson, D. C., & Hendricks, R. L. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.3.341 · Cited by 206
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
Alvarez-Breckenridge, C. A., Yu, J., Price, R., Wojton, J., Pradarelli, J., Mao, H., Wei, M., Wang, Y., He, S., Hardcastle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.3013 · Cited by 205
Self-citationThe Cycle of Human Herpes Simplex Virus Infection: Virus Transport and Immune Control
Cunningham, A. L., Diefenbach, R. J., Miranda‐Saksena, M., Bosnjak, L., Kim, M., Jones, C., & Douglas, M. W. (2006) · The Journal of Infectious Diseases · doi:10.1086/505359 · Cited by 203
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., Fisher, K., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002409 · Cited by 200
Park, S. H., Breitbach, C. J., Lee, J., Park, J. O., Lim, H. Y., Kang, W. K., Moon, A., Mun, J.-H., Sommermann, E. M., Maruri‐Avidal, L., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.109 · Cited by 195
Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity
Errington, F., Steele, L., Prestwich, R., Harrington, K. J., Pandha, H. S., Vidal, L., de Bono, J., Selby, P., Coffey, M., Vile, R., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6018 · Cited by 186
Galanis, E., Atherton, P. J., Maurer, M. J., Knutson, K. L., Dowdy, S. C., Cliby, W. A., Haluska, P., Long, H. J., Oberg, A., Aderca, I., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2533 · Cited by 179
Fulci, G., Dmitrieva, N., Gianni, D., Fontana, E. J., Pan, X., Lu, Y., Kaufman, C. S., Kaur, B., Lawler, S. E., Lee, R. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1063 · Cited by 173
Self-citationMeasles Virus for Cancer Therapy
Russell, S. J., & Peng, K. W. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-70617-5_11 · Cited by 172
Intralesional injection of herpes simplex virus 1716 in metastatic melanoma
MacKie, R. M., Stewart, B., & Brown, S. M. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04048-4 · Cited by 171
Kemeny, N., Brown, K., Covey, A., Kim, T., Bhargava, A., Brody, L., Guilfoyle, B., Haag, N. P., Karrasch, M., Glasschroeder, B., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1214 · Cited by 171
Galanis, E., Markovic, S. N., Suman, V. J., Nuovo, G. J., Vile, R. G., Kottke, T. J., Nevala, W. K., Thompson, M. A., Lewis, J. E., Rumilla, K. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.146 · Cited by 168
Cripe, T. P., Ngo, M. C., Geller, J. I., Louis, C. U., Currier, M. A., Racadio, J. M., Towbin, A. J., Rooney, C. M., Pelusio, A., Moon, A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.243 · Cited by 159
Gollamudi, R., Ghalib, M. H., Desai, K. K., Chaudhary, I., Wong, B., Einstein, M. H., Coffey, M. C., Gill, G. M., Mettinger, K. L., Mariadason, J. M., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9279-8 · Cited by 152
Perez, O. D., Logg, C. R., Hiraoka, K., Diago, O. R., Burnett, R., Inagaki, A., Jolson, D., Amundson, K., Buckley, T., Lohse, D., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.83 · Cited by 137
Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model
Jiang, H., Clise-Dwyer, K., Ruisaard, K. E., Fan, X., Tian, W., Gumin, J., Lamfers, M. L. M., Kleijn, A., Lang, F. F., Yung, W.-K. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097407 · Cited by 127
Oncolytic vaccinia virus for the treatment of cancer
Guse, K., Cerullo, V., & Hemminki, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.558838 · Cited by 123
Oncolytic adenoviruses – selective retargeting to tumor cells
Mathis, J. M., Stoff‐Khalili, M. A., & Curiel, D. T. (2005) · Oncogene · doi:10.1038/sj.onc.1209044 · Cited by 122
Rodríguez-García, A., Giménez-Alejandre, M., Rojas, J. J., Moreno, R., Bazán‐Peregrino, M., Cascalló, M., & Alemany, R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2213 · Cited by 121
Msaouel, P., Dispenzieri, A. A., & Galanis, E. (2009) · PubMed · Cited by 118
Encapsulated Stem Cells Loaded With Hyaluronidase-expressing Oncolytic Virus for Brain Tumor Therapy
Martínez‐Quintanilla, J., He, D., Wakimoto, H., Alemany, R., & Shah, K. (2014) · Molecular Therapy · doi:10.1038/mt.2014.204 · Cited by 118
Arulanandam, R., Batenchuk, C., Angarita, F. A., Ottolino‐Perry, K., Cousineau, S. E., Mottashed, A., Burgess, E., Falls, T. J., Silva, N. D., Tsang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.009 · Cited by 115
Kimball, K. J., Preuss, M. A., Barnes, M. N., Wang, M., Siegal, G. P., Wan, W., Kuo, H., Saddekni, S., Stockard, C. R., Grizzle, W. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0791 · Cited by 109
Aghi, M. K., Visted, T., DePinho, R. A., & Chiocca, E. A. (2008) · Oncogene · doi:10.1038/onc.2008.53 · Cited by 94
Self-citationType B Coxsackieviruses and Their Interactions with the Innate and Adaptive Immune Systems
Kemball, C. C., Alirezaei, M., & Whitton, J. L. (2010) · Future Microbiology · doi:10.2217/fmb.10.101 · Cited by 85
From Touchdown to Transcription: The Reovirus Cell Entry Pathway
Danthi, P., Ogden, K. M., Kirchner, E., Mainou, B. A., Stehle, T., & Dermody, T. S. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_32 · Cited by 83
Oncolytic polio virotherapy of cancer
Brown, M. C., Dobrikova, E. Y., Dobrikov, M. I., Walton, R. W., Gemberling, S. L., Nair, S. K., Desjardins, A., Sampson, J. H., Friedman, H. S., Friedman, A. H., et al. (2014) · Cancer · doi:10.1002/cncr.28862 · Cited by 82
Replication-competent retrovirus vectors for cancer gene therapy
Tai, C.-K. (2007) · Frontiers in bioscience · doi:10.2741/2910 · Cited by 78
Oncolytic measles virus strains as novel anticancer agents
Msaouel, P., Opyrchal, M., Domingo‐Musibay, E., & Galanis, E. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.749851 · Cited by 76
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma
Nakashima, H., Kaufmann, J. K., Wang, P.-Y., Nguyen, T., Speranza, M. C., Kasai, K., Okemoto, K., Otsuki, A., Nakano, I., Fernández, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80713 · Cited by 74
Self-citationThe oncolytic virus, pelareorep, as a novel anticancer agent: a review
Chakrabarty, R., Tran, H., Selvaggi, G., Hagerman, A., Thompson, B., & Coffey, M. C. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0216-8 · Cited by 74
MicroRNAs and oncolytic viruses
Ruiz, A. J., & Russell, S. J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.007 · Cited by 70
Huang, T., Parab, S., Burnett, R., Diago, O. R., Ostertag, D. G., Hofman, F. M., Espinoza, F. L., Martin, B., Ibañez, C. E., Kasahara, N., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.100 · Cited by 63
Freytag, S. O., Barton, K. N., & Zhang, Y. (2013) · Gene Therapy · doi:10.1038/gt.2013.40 · Cited by 58
Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus
Brown, M. C., & Gromeier, M. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.05.007 · Cited by 55
Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints
Jiang, H., Gomez‐Manzano, C., Rivera-Molina, Y. A., Lang, F. F., Conrad, C. A., & Fueyo-Margareto, J. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.009 · Cited by 51
Development of PROSTVAC Immunotherapy in Prostate Cancer
Singh, P. P., Pal, S. K., Alex, A. B., & Agarwal, N. (2015) · Future Oncology · doi:10.2217/fon.15.120 · Cited by 44
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic
Breitbach, C. J., Parato, K. A., Burke, J., Hwang, T.-H., Bell, J. C., & Kirn, D. H. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.016 · Cited by 44
Oncolytic viruses for the therapy of brain tumors and other solid malignancies a review
Chiocca, E. A. (2003) · Frontiers in bioscience · doi:10.2741/976 · Cited by 40
Self-citationOncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.
Brown, M. C., & Gromeier, M. (2015) · PubMed · Cited by 14
Cited by
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citation
Metadata
- Authors
- Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-06-01
- Volume
- 3
- Issue
- 6
- Pages
- 841
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2494461917
- Cited by
- 592
- References
- 73
- FWCI
- 29.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.